CompletedNot Applicable

Dose-Dependent Effects of Intraoperative Tranexamic Acid on Surgical Bleeding and Transfusion Requirements in Multilevel Thoracolumbar Spinal Surgery

Turkey (Türkiye)62 participantsStarted 2023-11-01

Plain-language summary

Multilevel spinal stabilization surgery is frequently associated with substantial blood loss and increased transfusion requirements. Tranexamic acid (TXA), an antifibrinolytic agent, reduces perioperative bleeding, but the optimal intravenous dosing regimen remains controversial. This study aimed to compare the efficacy and safety of two TXA dosing protocols in patients undergoing ≥3-level spinal stabilization surgery.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Between 18-65 years * Scheduled for elective ≥3-level spinal stabilization surgery under general anesthesia Exclusion Criteria: * History of thromboembolic events * Myocardial infarction * Stroke * Hepatic or renal failure, * Known allergy to TXA * Bleeding or coagulation disorders, * ASA physical status IV * Trauma or tumor surgery * Refusal to provide informed consent

What they're measuring

Intraoperative Blood Loss [Milliliters]

Timeframe: During the operation

Number of Patients Requiring Intraoperative Erythrocyte Suspension Transfusion [Number of Participants]

Timeframe: During the operation

Trial details

NCT IDNCT07288697

SponsorDr. Lutfi Kirdar Kartal Training and Research Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-04-01

View on ClinicalTrials.gov More Spinal Disorders trials